ScoreWhy is Astrazeneca Pharma India Ltd ?
1
Flat results in Dec 25
- PAT(Q) At Rs 31.55 cr has Fallen at -45.6% (vs previous 4Q average)
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 399.94 cr
- PBDIT(Q) Lowest at Rs 44.83 cr.
2
With ROE of 26.1, it has a Very Expensive valuation with a 27 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 10.00%, its profits have risen by 16.3% ; the PEG ratio of the company is 6.4
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Astrazeneca Phar for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Astrazeneca Phar
-36.96%
0.32
31.54%
Sensex
-11.84%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
25.05%
EBIT Growth (5y)
15.78%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
1.88
Tax Ratio
25.69%
Dividend Payout Ratio
47.99%
Pledged Shares
0
Institutional Holding
8.76%
ROCE (avg)
97.56%
ROE (avg)
20.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
83
Industry P/E
36
Price to Book Value
16.41
EV to EBIT
65.27
EV to EBITDA
60.37
EV to Capital Employed
32.72
EV to Sales
5.71
PEG Ratio
NA
Dividend Yield
0.63%
ROCE (Latest)
64.54%
ROE (Latest)
19.88%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET SALES(Latest six months)
At Rs 1,190.18 cr has Grown at 29.26%
-6What is not working for the Company
PBT LESS OI(Q)
At Rs 53.27 cr has Fallen at -12.6% (vs previous 4Q average
PAT(Q)
At Rs 45.71 cr has Fallen at -12.2% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Astrazeneca Phar
Net Sales - Latest six months
At Rs 1,190.18 cr has Grown at 29.26%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Astrazeneca Phar
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 53.27 cr has Fallen at -12.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 60.92 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 45.71 cr has Fallen at -12.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 52.07 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
